Searchable abstracts of presentations at key conferences in endocrinology

ea0081p406 | Pituitary and Neuroendocrinology | ECE2022

GLP-1 receptor agonists stimulate growth hormone release

Reppo Ingrid , Heinla Keiu , Sedman Tuuli , Volke Vallo

The secretion of growth hormone (GH) is under the feedback control of numerous nutritional and endocrine factors. The most widely used endocrine dynamic tests used to diagnose GH deficiency, insulin hypoglycemia test, and glucagon test, are time-consuming and cumbersome both for patients and medical personnel. There is an unmet need for easier to conduct, shorter, and safer diagnostic tests. We and other groups have previously demonstrated that acute administration of glucagon...

ea0049ep607 | Diabetes therapy | ECE2017

Does tolerance develop toward GLP-1 receptor agonists’ glucose-lowering effect?

Sedman Tuuli , Krass Maarja , Runkorg Kertu , Vasar Eero , Volke Vallo

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a popular tool for the treatment of type 2 diabetes. Unlike many other antidiabetic drug classes, distinct GLP-1 RAs have different therapeutic profiles, mostly due to their different pharmacokinetic properties. Animal experiments and human data indicate that tolerance develops toward at least some of their effects, e.g., gastric motility. Whether tolerance develops toward the glucose-lowering effect...

ea0086p238 | Neuroendocrinology and Pituitary | SFEBES2022

Anticoagulation practice for venous thromboembolism prophylaxis in patients with Cushing’s Syndrome - a Society for Endocrinology survey of UK Centres

Isand Kristina , Plummer Zoe E , Volke Vallo , Newell-Price John , Wass John , Pal Aparna

Background: Cushing’s syndrome (CS) is estimated to have a 10-fold increased risk of venous thromboembolism (VTE) compared with the normal population with VTE accounting for 3.6-11% deaths in CS patients. There are no specific guidelines for VTE prophylaxis in CS other than that it should be considered given the increasingly recognised risk.Methods: Via the Society for Endocrinology, we surveyed current VTE anticoagulation practice across UK Endocri...

ea0090oc3.6 | Oral Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Venous thrombotic events (VTE) across ERCUSYN: details of these VTE’s and do centres anticoagulate on a routine bases?

Isand Kristina , Feelders Richard , Brue Thierry , Toth Miklos , Deutschbein Timo , Reincke Martin , Krsek Michal , Vives Alicia Santos , Demtroder Frank , Chabre Olivier , J. Strasburger Christian , Wass John , Webb Susan M , Maso Ana Aulinas , Volke Vallo , Valassi Elena

For all ERCUSYN investigatorsBackground: Patients with Cushing’s syndrome (CS) have an increased risk of developing venous thromboembolic complications. There is currently no standard practise for thromboprophylaxis in CS patients.Aim: To study the details of VTE in patients included in The European Registry on Cushing’s syndrome (ERCUSYN) and study various thromboprophylaxis protocols used among the centres where VTE&#14...